PROSPECTS FOR INCREASING THE EFFICIENCY OF TREATMENT OF PATIENTS HEAVING OF LOCALLY- DISTRIBUTED BREAST CANCER
Abstract
Improving the efficiency of treatment of locally distributed forms of breast cancer (BC) patients is relevant.
The aim of the study: to determine the possibility of increasing the efficiency of treatment of patients with locally distributed BC by supplementing it with the determination of the expression of TOP2 alpha and beta-tubulin III genes in the primary tumor during various chemotherapy regimens.
Method. 139 patients with locally distributed BC were examined. Patients received 2-4 courses of neoadjuvant chemotherapy (NAChT) according to the TC (docetaxel + cyclophosphamide) and TAC (docetaxel + doxorubicin + cyclophosphamide) regimens, subsequent surgical intervention and 2–4 courses of AchT according to the FAC regimen. Immunohistochemical (IHCh) study of the levels of estrogen receptors (ER), progesterone (PR), epidermal growth factor (HER2) in tumors was conducted. The expression of TOP2 alpha and beta-tubulin class III genes was determined using PCR. Statistical data processing was performed using the program Stastistica for Windows 6. 0, Excel.
Results. In the third cycle of chemotherapy, patients were transferred from the TC scheme to the TAC scheme. The frequency of the FPR increased 4 times in the group of patients with a triple negative tumor subtype compared with patients with luminal B. A combination of low expression of the class III beta-tubulin gene with high expression of TOP2 alpha in tumor tissue was found in 64.5 % of patients treated according to the TAC + cross over regimen and in 56.3 % of cases according to the TC regimen. A change in the receptor status of MLN after NAChT was detected in some cases.
Conclusions. The combination of high expression of TOP2 alpha with low expression of class III beta-tubulins can be considered as a predictive sign of full pathomorphological response when using taxane-containing locally distributed BC. These markers can be recommended for determination in MLN (along with definition of ER, PR, HER2) in order to increase the effectiveness of AchT.
Downloads
References
Sadchikova, M. V., Siniavina, L. V., Otchenash, N. M. (2019). Role of hormone therapy in treatment of early breast cancer. International Medical Journal, 25 (2), 40–44.
National Cancer Register Bulletin- Cancer in Ukraine, 2016–2017 (2018). Kyiv, 19, 44–45. Available at: http://www.ncru.inf.ua/publications/BULL_19/PDF_E/44-45 %20shm.pdf
Semiglazov, V. F. (2013). New approaches to the treatment of breast cancer. Oncology Issues, 59 (3), 288–291.
Semiglazov, V. F., Bozhok, A. A., Semiglazova, T. Yu., Vasiliev, A. G., Manihas, A. G., Semiglazov, V. V. et. al. (2013) HER2-positive breast cancer: standard and dual targeted treatment. Oncology Issues, 59 (3), 341–346.
Semiglazova, T. Yu., Klimenko, V. V., Filatova, L. V., Chubenko, V. A., Krivorotko, P. V. et. al. (2013). Markers of the effectiveness of preoperative taxane-containing chemotherapy for locally advanced breast cancer. Oncology Issues, 59 (3), 363–368.
Cianfrocca, M., Goldstein, L. J. (2004). Prognostic and Predictive Factors in Early‐Stage Breast Cancer. The Oncologist, 9 (6), 606–616. doi: http://doi.org/10.1634/theoncologist.9-6-606
Soerjomataram, I., Louwman, M. W. J., Ribot, J. G., Roukema, J. A., Coebergh, J. W. W. (2007). An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Research and Treatment, 107 (3), 309–330. doi: http://doi.org/10.1007/s10549-007-9556-1
Bershtein, L. M. (2013). Endocrinology of breast cancer as a heterogeneous disease: a decade after the Millennium. Oncology Issues, 59 (3), 292–298.
Semiglazov, V. F., Krivorotko, P. V., Dashyan, G. A., Zhiltsova, E. K., Ivanova, O. A., Ivanov, V. G. et. al. (2017). Neoadjuvant systemic therapy of breast cancer (retrospective and prospective analysis). Oncology Issues, 63 (2), 256–260.
Dowlatshahi, K., Witt, T. R. et. al. (2000). Detection of occult micrometastases by 0.25 mm sectioning and cytokeratin staining of sentinel nodes in early breast cancer. ASCO, 305.
Klimenko, V. V. (2015). Molecular markers of the effectiveness of preoperative chemotherapy for locally advanced breast cancer. FGBU “SII of Oncology by N. N. Petrov”, 22.
Semiglazov, V. F., Semiglazov, V. V., Dashyan, G. A. (2010). Problems of surgical treatment of breast cancer (The usefulness of a biopsy of signal lymph nodes. Local surgical treatment. Journal of Practical Oncology, 11 (4), 217–220.
Vinnik, Yu. A., Belevtsova, Yu. Yu. (2018) Biological features of local –advanced breast cancer in primary tumor and metastases. Kharkiv surgical school, 5-6 (92-93), 56-59.
Belevtsova, Yu. Yu. (2019). Individualization of neoadjuvant rherapy in patients with locally-distributed breast cancer. International medical journal, 1, 65–69.
Wein, L., Luen, S. J., Savas, P., Salgado, R., Loi, S. (2018). Checkpoint blockade in the treatment of breast cancer: current status and future directions. British Journal of Cancer, 119 (1), 4–11. doi: http://doi.org/10.1038/s41416-018-0126-6
Robert, J., Morvan, V. L., Smith, D., Pourquier, P., Bonnet, J. (2005). Predicting drug response and toxicity based on gene polymorphisms. Critical Reviews in Oncology/Hematology, 54 (3), 171–196. doi: http://doi.org/10.1016/j.critrevonc.2005.01.005
Chabner, B. A., Roberts, T. G. (2005). Chemotherapy and the war on cancer. Nature Reviews Cancer, 5 (1), 65–72. doi: http://doi.org/10.1038/nrc1529
Guiu, S., Michiels, S., André, F., Cortes, J., Denkert, C., Di Leo, A. et. al. (2012). Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Annals of Oncology, 23 (12), 2997–3006. doi: http://doi.org/10.1093/annonc/mds586
Coon, J. S., Marcus, E., Gupta-Burt, S. et. al. (2002). Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clinical Cancer Research, 8 (4), 1061—1067.
Mozzetti, S., Ferlini, C., Concolino, P. et. al. (2005). Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clinical Cancer Research, 11 (1), 298–305.
Vincenzi, B., Cesa, A. L., Santini, D., Schiavon, G., Grilli, C., Graziano, F., Tonini, G. (2004). Predictive factors for response to chemotherapy in colorectal cancer patients. Critical Reviews in Oncology/Hematology, 52 (1), 45–60. doi: http://doi.org/10.1016/j.critrevonc.2004.05.005
Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V. et. al. (2005). Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and flu-orouracil or cyclophosphamide, epiru-bicin, and fluorouracil: Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 23 (30), 7483–7490.
Urano, N., Fujiwara, Y., Doki, Y., Kim, S., Miyoshi, Y., Noguchi, S., … Monden, M. (2006). Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. International Journal of Oncology, 28 (2), 375–381. doi: http://doi.org/10.3892/ijo.28.2.375
Liu, L., Gerson, S. L. (2006). Targeted modulation of MGMT: clinical implications. Clinical Cancer Research, 12 (2), 328–331. doi: http://doi.org/10.1158/1078-0432.ccr-05-2543
Prokopyuk, A. V., Knyazyeva, M. V. (2019). About epithelial-mesenchymal relationships in tumors of patients with stage III-IV ovarian cancer. White Nights. Saint Petersburg: Ed. ANNMO. Oncology Issues, 70.
Copyright (c) 2020 Yuri Vinnik, Yulia Belevtsova, Marina Sadchikova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.